Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multip...
April 29 2021 - 7:30AM
Business Wire
Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX)
("Brooklyn") today announced it has acquired an exclusive license
for mRNA gene editing and cell therapies technology of Factor
Bioscience Limited and Novellus Therapeutics Limited pursuant to an
exercise of a previously announced option.
The license includes use of an extensively patented process to
develop gene editing compounds using mRNA, which preclinical data
suggest demonstrate a high degree of efficiency, as well as being
non-immunogenic and non-mutagenic.
The licensed platform includes mRNA cell reprogramming, which is
considered to be the highest efficiency and footprint-free
technology that can be applied to both allogeneic and autologous
cells, and is combined with mRNA-based gene editing – along with a
proprietary gene editing protein – to eliminate off-target effects.
It also includes the proprietary ToRNAdo lipid delivery system that
provides efficient delivery of mRNA ex vivo and in vivo to skin,
brain, eye and lung tissue.
“As a result of the license acquisition, Brooklyn is now poised
to become a key player among companies exploring gene editing for
cell therapies. This mRNA gene editing technology has the potential
to be disruptive given its high efficiency and relatively low
manufacturing costs. We look forward to continuing the work begun
by Factor Bioscience and Novellus with this platform and to
reporting our progress as our products advance towards the clinic,”
commented Howard J. Federoff, M.D., Ph.D., Chief Executive Officer
and President of Brooklyn. “Our licensing of this technology
represents a significant advancement in our approach to treating
cancers, blood and other disorders, and transforms us from a single
therapeutic company with multiple potential indications to a
platform company with multiple products in a pipeline of
next-generation engineered cellular medicines.”
Brooklyn intends to initiate pre-clinical development programs
for sickle cell anemia, other inherited monogenic disorders, and
solid and liquid tumors, with the intention of being at the
Investigational New Drug (IND) stage for at least one of these
disorders by 2024.
About Brooklyn ImmunoTherapeutics
Brooklyn is exploring the role that cytokine-based therapy can
have in treating patients with cancer, both as a single agent and
in combination with other anti-cancer therapies. The company is
also exploring opportunities to advance oncology and blood disorder
therapies using leading edge gene editing/cell therapy technology
through the newly acquired license from Factor Bioscience and
Novellus.
Brooklyn’s most advanced program is studying the safety and
efficacy of IRX-2 in patients with head and neck cancer. In a Phase
2A clinical trial in head and neck cancer, IRX-2 demonstrated an
overall survival benefit. Additional studies are either underway or
planned in other solid tumor cancer indications.
For more information about Brooklyn and its clinical programs,
please visit www.BrooklynITx.com.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, concerning Brooklyn's expectations, anticipations,
intentions, beliefs or strategies regarding the future that are not
statements of historical fact, including statements in the fourth
and fifth paragraphs related to potential future development and
growth. These statements are based upon the current beliefs and
expectations of Brooklyn's management and are subject to
significant risks, uncertainties, and other factors. Brooklyn’s
actual results could differ materially from any anticipated future
results, performance, or achievements described in the
forward-looking statements as a result of a number of factors,
including, but not limited to: (i) Brooklyn’s ability to
successfully, cost-effectively and efficiently develop its
technology and products; (ii) Brooklyn’s ability to successfully
commence clinical trials of any products on a timely basis or at
all; (iii) Brooklyn’s ability to successfully fund and manage the
growth of its development activities; (iv) Brooklyn’s ability to
obtain regulatory approvals of its products for commercialization;
and (v) uncertainties related to the impact of the COVID-19
pandemic on the business and financial condition of Brooklyn,
including on the timing and cost of the BR-202 clinical trial.
Additional factors and risks are described in Brooklyn’s periodic
reports filed with the Securities and Exchange Commission, which
are available on the SEC's website at www.sec.gov. Forward-looking
statements are made based on information available to Brooklyn on
the date of this press release, and Brooklyn assumes no obligation
to update the information contained in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005406/en/
Investor Relations: CORE IR 516-222-2560
investors@brooklynitx.com
Media: MacDougall Nicholas Chang nchang@macbiocom.com
781-235-3060
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024